Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform

By Chemaxon Ltd., PRNE
Wednesday, August 18, 2010

Compound Registration, Structure Search and Computed Properties Rolled Out

BUDAPEST, Hungary and CAMBRIDGE, Massachusetts, August 19, 2010 - ChemAxon, a leading provider of chemistry software for life sciences,
announced today that they have entered into an agreement with the Broad
Institute of Harvard and MIT, which will license ChemAxon's platform,
discovery toolkits and desktop applications for institute-wide use. Broad
will support their legacy small molecule registration system and other
functionality across their Chemical Biology Platform with ChemAxon's

In addition to ChemAxon's discovery and desktop tools, the Broad
Institute has already updated their core technology for archiving small
molecules by deploying the JChem platform toolkit within their existing

"This adoption is a part of our strategy to provide our scientists in the
Chemical Biology Platform with the most modern and capable tools to
accelerate our research," said Michael Foley, Director of the Broad's
Chemical Biology Platform. "The extensive capabilities of the ChemAxon
software support our ongoing efforts to build and apply state of the art
facilities to support our work."

The evaluation and deployment is to be presented during ChemAxon's User
Group Meeting being held in Boston's Omni Parker House, September 14-15, the
complete program is here:

About ChemAxon

ChemAxon is a leader in providing cheminformatics software development
platforms and applications for the biotechnology, pharmaceutical and
agrochemical industries. With core capabilities for structure visualization,
search and management, property prediction, virtual synthesis, screening and
drug design, ChemAxon focuses upon active interaction with users and software
portability to create powerful, cost effective cross platform solutions and
programming interfaces to power modern cheminformatics and chemical
communication. For more information please visit

Alex Allardyce, Phone: +1-857-544-0541, E-Mail: aa at

will not be displayed